Ellen Foster Licking
In late August, Genzyme Corp. launched a hostile bid of $380 million for AnorMed Inc. , a Canadian biotech with...
Genzyme Breaks a Biotech Taboo: The Hostile Bid For AnorMED
In late August, Genzyme launched a hostile bid for AnorMED, a Canadian biotech with an unpartnered stem cell mobilizer called MOZOBIL currently in Phase III clinical trials. When Millennium Pharmaceuticals Inc. jumped in with a higher offer, it set off a bidding war that has been dubbed "The battle of Boston". Ultimately, Genzyme prevailed, but in deciding to go directly to AnorMED's shareholders with its bid, that company's management broke one of the last taboos of biotech M&A. The move illustrates business development execs' desperate need to nab suitable assets that might help cure pipeline woes. Indeed, it appears unencumbered late stage assets are now so rare that their value may exceed estimates ascribed by the market; and this is true even if the people working on that asset are lost, as typically occurs following unsolicited offers.
More from Business Strategy
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
• By
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
More from In Vivo
• By
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.